Abstract:
PURPOSE: A pharmaceutical composition for preventing or treating acute lung injury or an acute respiratory failure has excellent effect for preventing or treating acute lung injury or an acute respiratory failure by reducing lung edema and lung damage. CONSTITUTION: A pharmaceutical composition for preventing or treating acute lung injury or an acute respiratory failure includes a soluble RAGE (sRAGE) in a first sequence capable of being coupled to a ligand of a receptor for advanced glycation end products (RAGE), as an active ingredient. The sRAGE obstructs the coupling between the ligand of the RAGE and the RAGE. The RAGE is coupled to the Fc side of an immunoglobulin. The composition suppresses an inflammation. [Reference numerals] (AA) Normal type I & II alveolar epithelium cell; (BB) Neutroph, infiltration of monocyte and erythrocyte cell increase; (CC) Edema of alveolar epithelium cell is observed; (DD) Infiltration in alveolar decreases; (EE) Alveolar epithelium cell doesn't get demaged